{"filings":[{"id":833436,"accession_number":"0001193125-26-255396","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-06-03T20:02:22+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Xenon shareholders approve 2026 equity plan, elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved the 2026 Equity Incentive Plan: 58.6M for, 27.6M against, 842K abstain.","New plan authorizes 4.4M new shares plus up to 14.72M shares from the prior plan (subject to expiry/forfeiture).","All 8 director nominees elected; say-on-pay approved (82.2M for, 4.8M against), with 1-year frequency chosen.","PricewaterhouseCoopers reappointed as auditor (90.4M for, 27.7K withheld); auditor remuneration authority approved.","Voter turnout: 90.4M shares (93.54% of eligible) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93847,"accession_number":"0001193125-26-211843","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon reports positive Phase 3 X-TOLE2 data for azetukalner; NDA submission planned Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 X-TOLE2 met primary endpoint: median percent change in monthly FOS -53.2% (25mg) and -34.5% (15mg) vs -10.4% placebo (p<0.0001).","NDA submission to FDA planned Q3 2026 based on X-TOLE2 and X-TOLE data.","Cash and marketable securities $1.34B as of March 31; cash runway into 2029. Net loss $102.3M for Q1 2026.","Enrollment ongoing for additional Phase 3 studies: X-TOLE3 (FOS), X-ACKT (PGTCS), X-NOVA2/3 (MDD), X-CEED (BPD); X-NOVA2 topline H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93846,"accession_number":"0001193125-26-152834","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xenon increases inducement equity plan share reserve from 900k to 1.175M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended 2025 Inducement Plan to raise maximum shares reserved from 900,000 to 1,175,000, a 30.6% increase.","Shares are reserved exclusively for inducement grants (nonstatutory options, RSUs, etc.) to new employees.","Amendment approved by independent directors; shareholder approval not obtained per Nasdaq Rule 5635(c)(4).","Plan amended effective April 7, 2026; full text filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105792,"accession_number":"0001193125-26-106144","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xenon Pharma sets 2026 annual meeting for June 2; record date April 7","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for June 2, 2026.","Record date for notice and voting is April 7, 2026.","Company will use notice-and-access for both registered and non-registered investors.","Only common shares are entitled to vote at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105791,"accession_number":"0001193125-26-104199","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Xenon Pharmaceuticals raises $707.7M in public offering of common shares and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 12.2M common shares at $57.00 plus pre-funded warrants for 877,194 shares at $56.9999 each.","Underwriters exercised option to purchase an additional 1.7M common shares in full.","Net proceeds of approximately $707.7 million after underwriting discounts and estimated expenses.","Offering closed on March 12, 2026; warrants have $0.0001 exercise price and are immediately exercisable.","Lead underwriters include J.P. Morgan, Jefferies, TD Securities, Stifel, RBC Capital Markets, and William Blair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105790,"accession_number":"0001193125-26-097577","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xenon Phase 3 X-TOLE2 azetukalner meets primary endpoint; NDA submission Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint MPC: 25mg -53.2% vs placebo -10.4% (p<0.000000000006); placebo-adjusted -42.7%, outperforming Phase 2b.","Key secondary RR50: 54.8% (25mg) vs 20.8% placebo (p=0.00000008).","Safety consistent: most common TEAEs dizziness (20.5%), headache (8.8%), somnolence (8.8%), fatigue (7.6%).","NDA submission to FDA planned Q3 2026 for focal onset seizures.","Data to be presented as Late Breaking Science at AAN Annual Meeting in April 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105789,"accession_number":"0001193125-26-082520","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xenon files $400M ATM equity prospectus supplement; $291M already sold under prior program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to register up to $400M of common shares for at-the-market (ATM) sales.","Prior ATM sales total $291,084,564 as of filing date; prior program terminated.","Sales agents are Jefferies and Stifel; shares issuable under Sales Agreement dated Aug 2020 as amended.","Registration statement automatically effective on Form S-3 filed Aug 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105788,"accession_number":"0001193125-26-076530","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon reports 2025 net loss of $345.9M; Phase 3 X-TOLE2 data expected in March 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $345.9M in 2025 vs $234.3M in 2024; R&D expense rose to $300.9M on azetukalner Phase 3 trials.","Pro forma cash $716M (incl. $130M ATM in Q1 2026) extends runway into H2 2027.","Phase 3 X-TOLE2 topline data for azetukalner in focal onset seizures due first half of March 2026.","NDA submission for azetukalner in FOS planned H2 2026; 5 additional Phase 3 studies in epilepsy and depression enrolling.","Early-stage pipeline: Phase 1 data for XEN1701 (NaV1.7) and XEN1120 (KV7) pain candidates expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":7500000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122073,"accession_number":"0001193125-25-303862","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xenon Pharma amends inducement plan, increases share reserve to 900,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended 2025 Inducement Plan on Nov 24, 2025, increasing share reserve from 775,000 to 900,000 common shares.","Plan is exclusively for inducing new employees or rehires after a bona fide interruption of employment.","No shareholder approval sought under Nasdaq Listing Rule 5635(c)(4); plan meets inducement grant rules.","Awards include nonstatutory stock options, SARs, restricted stock units, restricted stock, and performance awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122072,"accession_number":"0001193125-25-262519","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon Q3 net loss $90.9M, Phase 3 FOS study fully enrolled, new CFO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $90.9M (vs $62.8M Q3 2024) on higher R&D spend; R&D expenses $77.1M (vs $57.0M).","Phase 3 X-TOLE2 FOS study completed enrollment (380 patients); topline data expected early 2026.","Phase 3 MDD (X-NOVA2/3) and BPD (X-CEED) studies continue recruiting; Phase 1 Nav1.7 and Kv7 studies underway.","Tucker Kelly appointed CFO to lead finance strategy ahead of azetukalner launch.","Cash $555.3M as of Sept 30, 2025; runway into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":7500000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122070,"accession_number":"0001193125-25-242583","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K/A","filed_at":"2025-10-17T23:59:59+00:00","items":["8.01","9.01","5.02"],"status":"ready","headline":"Xenon names Tucker Kelly CFO with $540k salary, 225k options, 30k RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tucker Kelly appointed CFO effective Oct 15, 2025; replaces interim CFO Ian Mortimer who remains CEO.","Kelly's base salary $540k; eligible for annual incentive up to 45% of base.","Granted inducement option for 225k shares at $41.90 (Oct 15 close) vesting over 4 years.","Granted 30k RSUs vesting 25% annually over 4 years.","Kelly previously CFO of Deciphera, led commercial transition; will support azetukalner launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122071,"accession_number":"0001193125-25-241546","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Xenon appoints Tucker Kelly as CFO; grants 225K options, 30K RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tucker Kelly named CFO effective Oct 15, 2025; previously CFO at Deciphera (acquired by Ono for $2.4B).","Annual base salary $540K; eligible for incentive up to 45% of base.","One-time inducement grant: options for 225K shares at $41.90 (closing price Oct 15).","One-time grant of 30,000 RSUs; both options and RSUs vest over 4 years.","Interim CFO Ian Mortimer steps down but remains President & CEO as lead candidate azetukalner enters Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138777,"accession_number":"0000950170-25-106529","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon Q2 net loss $84.7M; azetukalner Phase 3 X-TOLE2 enrollment complete, topline early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $84.7M vs $57.9M Q2 2024; R&D expenses rose to $75.0M from $49.7M on azetukalner trials.","Phase 3 X-TOLE2 (focal seizures) patient recruitment complete; topline data expected early 2026.","Phase 1 studies underway for XEN1120 (Kv7) and XEN1701 (Nav1.7) pain candidates.","Darren Cline appointed Chief Commercial Officer to lead commercial build for azetukalner launch.","Cash $624.8M as of June 30, 2025; funding expected into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":7500000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138776,"accession_number":"0000950170-25-093996","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Xenon CFO Sherry Aulin resigns; CEO Ian Mortimer appointed interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sherry Aulin resigned as CFO, effective June 30, 2025.","Ian Mortimer (President & CEO) appointed interim CFO effective June 30, 2025, serving as principal financial and accounting officer.","No change to Mortimer's compensation in connection with the appointment.","Mortimer's background previously disclosed in the April 24, 2025 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156230,"accession_number":"0000950170-25-082494","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Xenon Pharmaceuticals holds 2025 Annual Meeting; all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 8 director nominees elected with over 64M votes each; broker non-votes of 2.2M.","Advisory say-on-pay passed with 67.3M for, 2.1M against, 0.5M abstain.","Appointment of PricewaterhouseCoopers LLP as auditor approved (72.0M for, 34K withheld).","Auditor remuneration authority approved (72.0M for, 25K against, 11K abstain).","Approximately 94.1% of outstanding common shares voted at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156229,"accession_number":"0000950170-25-069183","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon Q1 net loss $65.0M; X-TOLE2 topline data shifted to early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $65.0M (vs $47.9M Q1 2024) on higher R&D spend of $61.2M; revenue $7.5M from Neurocrine milestone.","Cash and securities $691.1M (down from $754.4M Dec 2024); cash runway into 2027.","Phase 3 X-TOLE2 FOS study recruitment to complete in months; topline data now expected early 2026 (modest shift).","Phase 3 MDD (X-NOVA3) and bipolar depression studies on track to initiate mid-2025.","Phase 1 started for XEN1120 (Kv7); IND for XEN1701 (Nav1.7) expected Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":7500000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174689,"accession_number":"0000950170-25-040381","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xenon Pharmaceuticals sets 2025 annual meeting for June 4, record date April 7","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting of shareholders scheduled for June 4, 2025.","Record date for notice and voting is April 7, 2025.","Common shares are the only securities entitled to vote.","Issuer will use notice-and-access for both registered and non-registered investors.","Issuer will pay for distribution of materials to objecting beneficial owners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174688,"accession_number":"0000950170-25-033653","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Xenon Pharmaceuticals dismisses KPMG, appoints PwC as independent auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit Committee dismissed KPMG as independent registered public accounting firm on March 3, 2025.","No disagreements or reportable events with KPMG during 2024, 2023, or interim period through March 3, 2025.","Audit Committee approved engagement of PricewaterhouseCoopers LLP for fiscal year ending Dec 31, 2025.","No prior consultations with PwC regarding accounting principles or audit scope during the two most recent fiscal years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174687,"accession_number":"0000950170-25-029010","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Xenon reports 2024 net loss $234.3M; CFO resigns; Phase 3 azetukalner FOS data due H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss for 2024 was $234.3M ($65.7M Q4), vs $182.4M in 2023; R&D spend rose to $210.4M.","Cash and marketable securities $754.4M as of Dec 31, 2024; sufficient to fund operations into 2027.","Phase 3 X-TOLE2/3 azetukalner FOS topline data expected H2 2025; Phase 3 MDD and bipolar depression trials advancing.","CFO Sherry Aulin resigns effective June 30, 2025, for personal reasons; will advise through Aug 31, 2025.","Neurocrine collaboration milestone triggers $7.5M payment; Phase 1 study of Nav1.2/1.6 inhibitor initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174686,"accession_number":"0000950170-25-006495","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Xenon Pharmaceuticals CCO Christopher Von Seggern departs; consulting agreement through May 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Von Seggern ceased as Chief Commercial Officer on January 17, 2025.","Separation Agreement provides severance per 2020 offer letter and 2024 annual bonus.","Consulting Agreement through May 1, 2025; equity awards continue vesting until then.","No replacement named for the CCO role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191651,"accession_number":"0000950170-24-125374","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon Q3 2024 net loss $62.8M; X-TOLE2 topline data expected H2 2025; COO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $62.8M for Q3 2024, compared to $48.5M in Q3 2023; R&D expenses rose to $57.0M.","Cash and marketable securities $803.3M as of Sep 30, 2024; cash runway expected into 2027.","Phase 3 X-TOLE2 focal onset seizure study topline data anticipated in H2 2025.","Phase 3 MDD study X-NOVA2 expected to initiate by end of 2024.","Appointed Matt Ronsheim as COO, new senior executive; early-stage pipeline targeting multiple INDs in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208113,"accession_number":"0000950170-24-093933","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon reports Q2 net loss of $57.9M; cash $850.6M; Phase 3 epilepsy data H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q2 2024 was $57.9M, compared to $47.5M in Q2 2023.","Cash and marketable securities $850.6M as of June 30, 2024, down from $930.9M at Dec 31, 2023; cash runway into 2027.","Phase 3 X-TOLE2 top-line FOS data anticipated H2 2025; MDD Phase 3 study to start H2 2024.","R&D expenses $49.7M (Q2 2024) vs $44.0M (Q2 2023); G&A $19.4M vs $11.6M.","Pre-clinical Kv7 and Nav1.7 candidates advancing; multiple INDs expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225674,"accession_number":"0000950170-24-069318","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Shareholders approve all proposals at annual meeting including 5.2M share increase to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 8 director nominees elected, e.g., Dawn Svoronos 61.5M For vs 4.5M Against; broker non-votes 2.6M.","Say-on-pay advisory vote approved: 64.0M For, 2.0M Against, 0.01M abstain.","Equity plan amendments approved to increase share reserve by 5,200,000 common shares: 63.1M For, 2.8M Against.","KPMG LLP appointed as independent auditor for 2024: 66.7M For, 1.8M Withheld.","Auditor remuneration authority approved: 65.7M For, 0.39M Against, 0.01M Abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225673,"accession_number":"0000950170-24-056940","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon Q1 net loss $47.9M; MDD Phase 3 on track for H2 2024 start","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $47.9M for Q1 2024, up from $41.7M in Q1 2023; cash and securities $885.4M.","R&D expenses rose to $44.3M from $39.5M, driven by azetukalner manufacturing and personnel costs.","Phase 3 MDD program to start H2 2024 after successful FDA interactions; X-TOLE2 enrollment completion expected late 2024 to early 2025.","WHO and USAN approved 'azetukalner' as generic name for XEN1101, a Kv7 potassium channel opener.","Other income increased to $11.5M from $7.6M on higher interest; cash expected to fund operations into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225672,"accession_number":"0000950170-24-046023","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Xenon Pharmaceuticals chair Simon Pimstone and director Mohammad Azab not standing for re-election","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chair Simon Pimstone and board member Mohammad Azab will not stand for re-election at 2024 annual meeting.","Both directors will continue to serve until the AGM; departures are not due to any disagreement with company.","No replacements announced yet; board size and composition will change after AGM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244826,"accession_number":"0000950170-24-028784","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xenon sets June 4, 2024 annual meeting; record date April 5","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting of shareholders scheduled for June 4, 2024.","Record date for notice and voting is April 5, 2024.","Common shares are the only securities entitled to vote.","Notice-and-access not used for registered or non-registered investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244825,"accession_number":"0000950170-24-023080","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon Pharma reports FY2023 net loss $182.4M, cash $930.9M; XEN1101 Phase 3 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $44.7M in Q4 2023 and $182.4M for FY2023, vs $37.4M and $125.4M in 2022.","R&D expenses $41.1M in Q4, $167.5M for FY2023, driven by XEN1101 Phase 3 epilepsy trials.","Cash and marketable securities $930.9M as of Dec 31, 2023; expected runway into 2027.","X-TOLE2 Phase 3 epilepsy patient enrollment expected to complete late 2024 to early 2025.","End-of-Phase 2 meeting with FDA for XEN1101 in major depressive disorder planned in April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262272,"accession_number":"0000950170-23-067040","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2023-11-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Xenon Pharmaceuticals raises ~$281.6M in underwritten public offering of shares and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net proceeds ~$281.6M from sale of 8,461,542 common shares and 769,230 pre-funded warrants at $32.50 per share/warrant.","Underwriters: J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets.","Underwriters granted 30-day option to purchase up to an additional 1,384,615 common shares.","Pre-funded warrants exercisable at $0.0001 per share, with 4.99% beneficial ownership limitation (adjustable to 19.99%).","Offering made under existing shelf registration statement (Oct 2021); underwriting agreement dated November 29, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262271,"accession_number":"0000950170-23-066032","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xenon reports Phase 2 XEN1101 MDD trial misses primary endpoint but hits secondary measures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MADRS at week 6: placebo reduction 13.90; XEN1101 20 mg reduction 16.94 (p=0.135), not statistically significant.","HAM-D17 (p=0.042) and anhedonia SHAPS (p=0.046) secondary endpoints met statistical significance for 20 mg.","Early onset: MADRS at week 1 showed significance for 20 mg (p=0.047); CGI-I also significant (p=0.004).","XEN1101 well tolerated; no SAEs in active arms; common TEAEs: dizziness (17.9%), somnolence (10.7%), headache (8.9%).","Company exploring future MDD development; XEN1101 also in Phase 3 epilepsy with no titration required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262270,"accession_number":"0000950170-23-062022","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xenon partner Neurocrine's Phase 2 trial of NBI-921352 in focal seizures fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 study of NBI-921352 in adult focal onset seizures failed to show meaningful seizure reduction.","Neurocrine will not pursue further development of NBI-921352 in focal onset seizures.","Xenon to review data for potential implications on ongoing SCN8A-developmental epileptic encephalopathy study.","Neurocrine continues pre-clinical development of dual selective Nav1.2/1.6 inhibitor under collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262269,"accession_number":"0000950170-23-061119","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon Q3 net loss $48.5M; XEN1101 MDD trial topline due late Nov–mid Dec","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $48.5M in Q3 2023 vs $37.2M in Q3 2022; cash $639.1M, funding operations into 2026.","XEN1101 Phase 2 X-NOVA MDD trial topline results expected late November to mid-December 2023.","Phase 3 epilepsy trials X-TOLE2, X-TOLE3, X-ACKT ongoing; X-TOLE2 enrollment to complete H2 2024.","Neurocrine to report NBI-921352 adult focal study data in November 2023.","R&D expenses increased to $42.9M from $29.4M, driven by XEN1101 clinical advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279467,"accession_number":"0000950170-23-040608","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon reports Q2 net loss $47.5M; XEN1101 MDD trial fully enrolled with data expected late Nov-Dec","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $47.5M vs $31.2M YoY; R&D expenses doubled to $44.0M on XEN1101 Phase 3 and MDD trials.","Cash $652.2M (down from $720.8M); sufficient to fund operations into 2026.","Last patient enrolled in XEN1101 Phase 2 X-NOVA MDD trial; topline data expected late Nov to mid-Dec 2023.","Phase 3 epilepsy trials X-TOLE2/3 and X-ACKT continue; partnered NBI-921352 Phase 2 data expected Q4 2023.","Webinar on MDD mechanism and X-NOVA design scheduled for mid-September."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279466,"accession_number":"0000950170-23-039782","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xenon appoints Dr. Gillian Cannon and Justin Gover to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Cannon brings 30+ years of pharma experience; held senior roles at Merck, UCB, Otsuka, and Roivant.","Justin Gover was founding CEO of GW Pharma (sold for $7.2B) and led development of Epidiolex for epilepsy.","Appointments effective August 8, 2023; both will receive standard non-employee director compensation.","Their expertise aligns with Xenon's advancing XEN1101 in Phase 3 epilepsy trials and Phase 2 MDD study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297861,"accession_number":"0000950170-23-026070","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xenon Pharmaceuticals announces results of 2023 annual meeting; all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 8 director nominees elected; highest vote count 50.7M (Svoronos, Gannon), lowest 48.5M (Machado).","Say-on-pay advisory vote approved: 44.2M for, 6.7M against, 3.3K abstain; 1.9M broker non-votes.","KPMG appointed as auditor with 51.5M votes for, 1.3M withheld.","Auditor remuneration authority approved: 50.7M for, 284K against, 2.8K abstain; 1.8M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297860,"accession_number":"0000950170-23-019727","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon reports Q1 2023 net loss $41.7M; advances XEN1101 Phase 3 epilepsy trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $41.7M ($0.66 per share) vs $19.7M in Q1 2022; no revenue recognized.","R&D expenses $39.5M, up $20.2M YoY driven by XEN1101 Phase 3 studies and X-NOVA MDD trial.","Cash $687.3M as of March 31, 2023; expects to fund operations into 2026.","XEN1101 Phase 3 epilepsy trials (X-TOLE2, X-TOLE3, X-ACKT) recruiting; pediatric expansion to include children ≥12.","Phase 2 X-NOVA MDD study last patient screening expected June 2023; topline data Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318111,"accession_number":"0000950170-23-007858","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xenon Pharmaceuticals adopts Executive Incentive Plan; sets 2023 salaries and 2022 bonuses for executives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Ian Mortimer: 2022 non-equity bonus $343,422; 2023 base salary $665,000.","CFO Sherry Aulin: 2022 bonus $178,619; 2023 base salary $465,000.","CMO Christopher Kenney: 2022 bonus $195,300; 2023 base salary $510,000.","CEO eligible for up to 60% base salary under new plan; CFO and CMO eligible for up to 40%.","Incentive Compensation Plan allows cash awards based on corporate goals (R&D, regulatory, financial milestones)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318110,"accession_number":"0000950170-23-006719","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xenon sets June 1, 2023 annual meeting; record date April 4, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting scheduled for June 1, 2023.","Record date for notice and voting is April 4, 2023.","Only common shares are entitled to vote at the meeting.","Issuer will not use notice-and-access for either registered or non-registered investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318109,"accession_number":"0000950170-23-005549","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon reports FY2022 net loss of $125.4M; cash $720.8M; XEN1101 Phase 3 ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $125.4M for FY2022 vs $78.9M in 2021; Q4 net loss $37.4M.","Revenue $9.4M for FY2022 vs $18.4M in 2021; no Q4 revenue.","Cash and marketable securities $720.8M as of Dec 31, 2022; sufficient into 2026.","XEN1101 Phase 3 epilepsy trials (X-TOLE2, X-TOLE3, X-ACKT) enrolling; topline MDD data expected Q3 2023.","Neurocrine partner Phase 2 FOS data expected H2 2023; XEN496 Phase 3 EPIK completion expected 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":9434000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336390,"accession_number":"0000950170-22-023202","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenon Q3 net loss $37.2M; launches XEN1101 Phase 3 epilepsy program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.1M vs $8.1M YoY; no Neurocrine milestone in Q3 2022.","Cash $752.2M as of Sep 30, 2022; expected runway into 2026.","XEN1101 Phase 3 trials X-TOLE2, X-TOLE3 (FOS) and X-ACKT (PGTCS) initiated.","X-NOVA MDD Phase 2 topline data expected Q3 2023.","R&D expenses $29.4M, up 56% YoY, driven by XEN1101 program."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":9434000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336389,"accession_number":"0000950170-22-022588","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xenon Pharma appoints Andrea DiFabio as Chief Legal Officer and Corporate Secretary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrea DiFabio joined Xenon as Chief Legal Officer and Corporate Secretary effective Nov 7, 2022.","She previously served as Chief Legal & Admin Officer at Repertoire Immune Medicines (2020-2022).","DiFabio held CLO roles at Codiak Biosciences and Bioverativ; earlier experience at Biogen and Parexel.","She will lead global legal strategy as Xenon advances late-stage epilepsy clinical programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353790,"accession_number":"0001564590-22-028750","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenon Pharma Q2 net loss $31.2M; XEN1101 Phase 3 on track for H2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $31.2M for Q2 2022, up from $22.1M in Q2 2021.","Cash and securities $788.2M as of June 30, 2022, extended runway into 2026.","Revenue fell to $0.5M from $2.2M, mainly due to wind-down of Neurocrine collaboration.","XEN1101 Phase 3 X-TOLE2 expected to start in H2 2022 after positive FDA End-of-Phase 2 meeting.","XEN496 EPIK study for KCNQ2-DEE anticipated to complete in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":9302000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371614,"accession_number":"0001564590-22-024065","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2022-06-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xenon Pharmaceuticals announces public offering of 7.87M shares and pre-funded warrants for net proceeds of ~$234.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 7,868,854 common shares and pre-funded warrants for 327,868 shares at $30.50/share and $30.4999/warrant.","Net proceeds expected ~$234.6M after underwriting discounts and estimated expenses.","Underwriters granted 30-day option to purchase up to 1,229,508 additional common shares at $28.67/share.","Pre-funded warrants exercisable immediately at $0.0001 per share until exercised in full."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371613,"accession_number":"0001564590-22-023664","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xenon announces positive FDA EOP2 meeting for XEN1101; Phase 3 to start H2 2022","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA aligned on key Phase 3 elements; NDA submission planned after completion of X-TOLE2 trial plus existing Phase 2b data.","XEN1101 Phase 3 program in focal onset seizures to begin second half 2022.","Plans to initiate single Phase 3 trial (X-ACKT) for primary generalized tonic clonic seizures.","Phase 2b X-TOLE met primary endpoint with p<0.001 across all doses; drug was well tolerated.","Xenon expects differentiated profile based on Kv7 potassium channel mechanism and once-daily no-titration dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371612,"accession_number":"0001564590-22-022228","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Xenon shareholders approve 5.3M share equity plan increase; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment to 2014 Equity Plan approved: 35.6M for, 6.2M against, 5.1M broker non-votes.","Total share reserve under plan increased to ~13.37M shares (includes prior reserves and 5.3M addition).","All eight director nominees elected with strong majority (e.g., Simon Pimstone 40.9M for).","Say-on-pay advisory vote passed: 41.1M for, 0.6M against.","KPMG reappointed as auditor with 45.9M for, 1.0M withheld."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371611,"accession_number":"0001564590-22-019282","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenon Q1 net loss $19.7M; XEN1101 Phase 3 on track for H2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.7M vs $15.8M YoY; revenue $8.8M, up from $4.4M on Neurocrine milestone.","Cash $537.9M, sufficient to fund operations into at least 2024.","XEN1101 Phase 2b met primary endpoint; FDA End-of-Phase 2 meeting Q2 2022; Phase 3 start H2 2022.","Phase 2 X-NOVA for MDD initiated; topline results expected in 2023.","XEN496 Phase 3 EPIK in KCNQ2-DEE ongoing; completion anticipated in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":8766000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390569,"accession_number":"0001564590-22-011356","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2022-03-22T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Xenon issues 1.016M common shares on conversion of all Series 1 Preferred held by BVF Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Converted 1,016,000 Series 1 Preferred Shares into 1,016,000 common shares.","Transaction was exempt under Section 3(a)(9) of the Securities Act.","No Series 1 Preferred Shares remain outstanding after the conversion.","BVF Partners L.P. affiliated funds were the sole holders of the converted shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390568,"accession_number":"0001564590-22-009639","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Xenon: director Hayden not standing for re-election; Pimstone to become Chair; exec comp approved","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Hayden will not stand for re-election at June 1, 2022 annual meeting; no disagreement with company.","Board appointed Dr. Pimstone as Chair of the Board, effective subject to his re-election as director.","2022 base salaries: Pimstone $525k, Mortimer $594k, Aulin $425k; retroactive to Jan 1, 2022.","2022 performance goals include XEN1101 Phase 3 start and MDD proof-of-concept trial initiation.","2021 non-equity incentive payments: Pimstone $450k, Mortimer $400k, Aulin $155k (in USD)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390567,"accession_number":"0001564590-22-008072","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Xenon Pharmaceuticals enters amended ATM equity offering agreement for up to $250M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to August 2020 ATM sales agreement with Jefferies and Stifel, filed March 1, 2022.","Company may offer and sell up to $250 million of common shares at-the-market on Nasdaq.","Sales agents Jefferies and Stifel will receive up to 3.0% commission on gross proceeds.","No minimum obligation to sell; program may be terminated by either party upon written notice.","Shares sold under existing shelf registration statement (File No. 333-260010) and prospectus supplement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390566,"accession_number":"0001564590-22-008039","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenon reports FY2021 net loss $78.9M; XEN1101 Phase 3 expected H2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $78.9M vs $28.8M in 2020; revenue $18.4M vs $32.2M.","Cash $551.8M (Dec 31, 2021) vs $177.0M; expects funding into at least 2024.","XEN1101 Phase 2b met primary endpoint; end-of-Phase 2 FDA meeting Q2 2022; Phase 3 start H2 2022.","XEN496 Phase 3 EPIK trial for KCNQ2-DEE enrolling; completion expected H1 2023.","Partner Neurocrine Phase 2 for NBI-921352 ongoing; Pacira Phase 1b for PCRX301 data expected Q2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":18437000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390565,"accession_number":"0001564590-22-001074","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2022-01-12T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Xenon Pharma receives $15M milestone from Neurocrine after FDA accepts pediatric epilepsy study expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA accepted protocol amendment to expand Phase 2 study of NBI-921352 to children aged 2–11 with SCN8A-DEE.","Xenon receives aggregate $15M: $6.75M cash plus $8.25M equity (258,986 shares at $31.855, a 15% premium to 30-day VWAP).","Full IND acceptance triggered per amendment to 2019 Collaboration Agreement with Neurocrine Biosciences.","Neurocrine's NBI-921352 is a selective Nav1.6 sodium channel inhibitor; two ongoing Phase 2 trials in epilepsy.","Xenon potential for future clinical, regulatory, and commercial milestones plus royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-01-12T23:59:59+00:00|390565"}